Nick Stone: Hello, everyone. It s Nick Stone, Head of Investor Relations. Welcome to our Year-to-Date and Q3 2023 Results Conference Call and Webcast for Investors and Analysts.
Deborah Waterhouse, chief executive of ViiV Healthcare, which specialises in the treatment of HIV/AIDS, said the company wants to release an annual jab within the next decade.
GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.